Jagetia G C
Department of Radiobiology, Kasturba Medical College, Manipal, India.
Strahlenther Onkol. 1994 Nov;170(11):648-53.
BACKGROUND/AIM: Radiotherapy of tumors is often accompanied by inadvertant side effects on the normal tissues after completion of the treatment, which may later on result in the development of secondary neoplasia. Aim was to investigate the effect of combination of radiosensitizing agents in combination with a radioprotector on the frequency of micronuclei in mouse bone marrow and to find out whether the administration of combination of radiosensitizing agents in combination with a radioprotective drug before irradiation will offer any significant advantage over the drugs used singly.
Female BALB/c mice were divided into 8 groups according to the treatment they received viz. 1. DDW (double distilled water), 2. chlorpromazine (CPZ) 10 mg/kg body-weight, 3. CPZ 15 mg/kg body-weight 4. bleomycin (BLM), 5. WR-2721, 6. CPZ (10 mg) + WR-2721, 7. CPZ (15 mg) + WR-2721, 8. BLM + WR-2721. After 30 min of drug/s administration the animals were exposed to either 0 or 4 Gy of 60Co g-radiation. The animals were killed at 24 h post-irradiation by cervical dislocation and the micronuclei were prepared according to the method described by Jagetia [17].
The administration of CPZ (10 or 15 mg) alone increased the frequency of micronuclei significantly when compared to the DDW treatment. The exposure of mice with 4 Gy resulted in a significant increase in the frequency of micronuclei compared to the concurrent control groups. The frequency of micronuclei increased significantly in CPZ (15 mg) and BLM + irradiated groups. However, treatment with WR-2721 before irradiation reduced the frequency of micronuclei by approximately 50% of the DDW + irradiated group. A further reduction in the frequency of micronuclei was observed when WR-2721 was combined with CPZ (10 and 15 mg) before irradiation. A combination of BLM with WR-2721 also resulted in a nonsignificant reduction in the frequency of micronuclei.
背景/目的:肿瘤放疗结束后,常伴随对正常组织的意外副作用,这可能随后导致继发性肿瘤的发生。目的是研究放射增敏剂与放射保护剂联合使用对小鼠骨髓微核频率的影响,并确定在照射前给予放射增敏剂与放射保护药物的联合用药是否比单独使用药物具有显著优势。
雌性BALB/c小鼠根据接受的治疗分为8组,即:1. 双蒸水(DDW);2. 氯丙嗪(CPZ)10mg/kg体重;3. CPZ 15mg/kg体重;4. 博来霉素(BLM);5. WR-2721;6. CPZ(10mg)+WR-2721;7. CPZ(15mg)+WR-2721;8. BLM+WR-2721。给药30分钟后,动物接受0或4Gy的60Coγ射线照射。照射后24小时,通过颈椎脱臼处死动物,并按照Jagetia[17]描述的方法制备微核。
与DDW处理相比,单独给予CPZ(10或15mg)显著增加了微核频率。与同期对照组相比,接受4Gy照射的小鼠微核频率显著增加。CPZ(15mg)组和BLM+照射组的微核频率显著增加。然而,照射前用WR-2721治疗可使微核频率降低至DDW+照射组的约50%。照射前将WR-2721与CPZ(10和15mg)联合使用时,微核频率进一步降低。BLM与WR-2721联合使用也使微核频率有不显著的降低。